Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
This duo maximizes results, especially when paired with moderate exercise and high-protein nutrition
Bifidobacterium longum, Lactobacillus rhamnosus
Tirzepatide targets both GLP-1 and GIP receptors, which may produce somewhat greater weight loss in some patients
Retatrutide is an investigational peptide drug developed by Eli Lilly that acts as a triple agonist, simultaneously targeting three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
US$ 23.82
US$ 29.97
US$ 23.85
